Bachem Holding AG (BANB.SW) Stock
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs).
Valuation
Financials & Margins
Latest News
Valuation & Return Ratios
Peer Comparison
About Bachem Holding AG
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Bachem Holding AG is led by CEO Anne-Kathrin Stoller, employs 2,511 people, headquartered in Bubendorf, CH, publicly traded since 1998.
over the past 52 weeks the stock has ranged between $48.52 and $83.25, and currently trades 10.5% below its 52-week high.
Official website: www.bachem.com